Compliance June 22, 2015

SEC Intends to Charge State Street for Solicitation Practices

Last year, State Street revealed it was under investigation for its solicitation of asset-servicing business for public retirement plans.
Reported by

State Street Corporation announced in an 8-K filing that the enforcement staff of the U.S. Securities and Exchange Commission has provided it with a “Wells” notice.

The notice relates to a previously disclosed SEC investigation into State Street’s solicitation of asset servicing business for public retirement plans and, specifically, its relationships with particular clients in two states during a period ending in 2011. The investigation includes State Street’s use of consultants and lobbyists and, in at least one instance, political contributions by one of its consultants during and after a public bidding process.

Never miss a story — sign up for PLANSPONSOR newsletters to keep up on the latest retirement plan benefits news.

The issuance of a Wells notice provides State Street with the opportunity to make a submission to the Commission in response to the SEC staff’s position, and State Street says intends to submit a response. A spokesperson for State Street told PLANSPONSOR’s sister publication CIO the firm “eliminated the hiring of consultants and lobbyists for our asset servicing dealings with U.S. public retirement plans in support of our sales efforts” three years ago.

When it disclosed the SEC investigation last year, State Street noted, “adverse outcomes could have a material adverse effect on our business and reputation.”

Benefits June 22, 2015

Catastrophic Claims Warrant Use of Stop-Loss Insurance

A report reveals the top 10 catastrophic claim conditions and highest-cost stop-loss claims, as well as emerging trends and considerations for employers with self-funded health benefits.
Reported by

For the risk that there will be a catastrophic health benefits claim, employers with self-funded health benefits generally purchase stop-loss insurance.  

A report from the U.S. business group of Sun Life Financial reveals cancer remains the costliest disease, accounting for more than one quarter (25.7%) of the $2.1 billion Sun Life paid out to stop-loss claimants during the report’s four-year period. The top three conditions, which include cancer (malignant neoplasm and leukemia/lymphoma/multiple myeloma) and end-stage renal disease, made up 33.5% of total reimbursement costs.

Get more!  Sign up for PLANSPONSOR newsletters.

One of the other top contributors to catastrophic claims costs is intravenous medications, which accounted for over $71.4 million, or 13%, of the total paid stop-loss claims during 2014. The top 20 intravenous medications are quite expensive and represent 65% of the total cost of intravenous medications administered for catastrophic claims conditions. Approximately half of the top 20 intravenous medications identified in the report are used to treat cancer, and represent nearly $25 million in treatment costs in 2014 alone.

The report also shows that individuals with claims in excess of $1 million remain a major driver of stop-loss payments, accounting for $348 million of the total paid stop-loss claims. Cancer, congenital anomalies (conditions present at birth), and premature births account for 28% of all claims breaching the $1 million mark.

The findings confirm the need for self-funded employers to protect against common health events that could turn into catastrophic claims. “Through our research, we are able to provide insight to the market on the conditions that drive high-cost claims and how self-funded employers can manage that risk effectively,” said Sun Life’s Brad Nieland, vice president, stop-loss.

The full report may be accessed here. A free registration is required.

«